Vivian Berlin

Executive Director, HMS

Displaying: 1 - 10 of 19 Results

Regenerative Cell Therapy for Skeletal Muscle Disorders

A startup emerging from Lee Rubin's lab aims to provide a long-term cell therapy regenerative solution for conditions that result in reduced or improper skeletal muscle regeneration. (Image credit: B.D. Colen/Harvard Staff.)Cell therapies hold…

Investigators

  • Lee L. Rubin

Polymixin synergistic novobiocin analogs for efficacious and safer treatment of Gram negative infections

The lipopolysaccharide (LPS) containing outer membrane of Gram-negative bacteria prevent penetration of antibiotics, making them ineffective against infections. Polymyxins, including colistin, bind LPS and disrupt the outer membrane and hence are…

Investigators

  • Daniel E. Kahne

Stapled peptide that inhibits bacterial transporter

Multidrug-resistant infection has become a worldwide epidemic in recent years especially in hospitals and other community-associated settings, causing great suffering of patients and huge healthcare burden. According to CDC, at least 23,000 people…

Investigators

  • Martin Karplus

Novel antibiotics against Gram-negative and drug-resistant bacterial pathogens

Dr. Kahne has a pipeline of programs aimed at developing first-in-class antibiotics:Program I: Potentiator of polymixin, increasing its therapeutic index for treatment of drug-resistant infectionsIn vitro: Novel agent potentiates activity of…

Investigators

  • Daniel E. Kahne

aP2 knock-out mice

AP2 knock-out mutant mice were developed by Dr. Gokhan Hotamisligil at Harvard Medical School (Science. 1996 Nov 22;274(5291):1377-9). AP2, also known as Fatty Acid-Binding Protein 4 (FABP4), encodes the adipocyte FABP. It plays important roles in…

Investigators

  • Gokhan S. Hotamisligil

KRT14-Cre mouse line

Hemizygous Tg(KRT14-cre)1Amc/J (also known as K14-Cre) transgenic mice were developed in the laboratory of Dr. Andrew P. McMahon at Harvard University. The mouse strain harbors Cre recombinase under the control of human keratin-14 promoter, which…

Investigators

  • Andrew P. McMahon

Ngn3-Cre transgenic mice for studying pancreatic development

Hemizygous transgenic Tg(Neurog3-cre/Esr1*)1Dam/J mice (also known as Ngn3/CreERTM) were developed in the laboratory of Dr. Douglas A. Melton at Harvard University. The mice contain a fusion protein of Cre recombinase and mutant mouse estrogen…

Investigators

  • Douglas Melton

A transgenic reporter system can be used for recombination-mediated modulation of gene activity in the developing mouse embryo

A transgenic reporter system consisting of a tamoxifen-inducible form of Cre recombinase (Cre-ERTM) that can be used for recombination-mediated modulation of gene activity in the developing mouse embryo. Using the enhancer of the Wnt1 gene to…

Investigators

  • Andrew P. McMahon
  • Paul S. Danielian
  • David H. Rowitch

In vitro models and method of treatment for amyotrophic lateral sclerosis (ALS)

It has been impossible to isolate viable human motor neurons from patients or from postmortem samples to investigate the mechanisms leading to neural degeneration in ALS. A potential solution is to use embryonic stem cells (ESC) as a renewable…

Investigators

  • Kevin Carl Eggan
  • Francesco Paolo Di Giorgio

Using (-)-indolactam V to induce differentiation of human and mouse embryonic stem cells into pancreatic lineage

• ILV can be used alone, or in combination with growth factors, to direct differentiation of ESCs into pancreatic specification. ILV is effective on human ESC lines and mouse ESC lines. • ILV is effective on human ESC lines HUES 2, 4 and 8. After 4…

Investigators

  • Douglas Melton
  • Shuibing Chen
  • Malgorzata Borowiak
  • Julia L. Fox
  • Stuart L. Schreiber
  • Lee F. Peng
  • Lee L. Rubin
  • Kelvin Lam
  • Lance Davidow

Page 1 of 2